644 results on '"Hatta, Yoshihiro"'
Search Results
2. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group
3. Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis
4. Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols
5. Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
6. Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
7. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects
8. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis
9. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
10. Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation
11. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group
12. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma
13. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations
14. Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
15. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia
16. Space disinfection using TiO2 photocatalyst reduces the incidence of febrile neutropenia in cancer patients
17. Long‐term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open‐label extension study following a phase 3 placebo‐controlled, double‐blind, parallel‐group study
18. JSH practical guidelines for hematological malignancies, 2018: I. leukemia—3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL)
19. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
20. Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor
21. Sensitive typing of reverse ABO blood groups with a waveguide-mode sensor
22. One percent chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies
23. Enhanced perforin expression associated with dasatinib therapy in natural killer cells
24. PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
25. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group
26. Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival
27. Increased Arbekacin Clearance in Patients With Febrile Neutropenia
28. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
29. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL
30. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
31. Pulmonary Veno-Occlusive Disease after Autologous Stem Cell Transplantation
32. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy
33. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
34. Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
35. Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study
36. Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study
37. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience
38. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts
39. Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease among diabetes mellitus patients undergoing allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective study
40. Mycotic pseudoaneurysm of a pulmonary artery branch caused by Cladosporium
41. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
42. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
43. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
44. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior
45. Plasma cell maturity as a predictor of prognosis in multiple myeloma
46. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies
47. Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood
48. Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study
49. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)
50. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo‐controlled, double‐blind, parallel‐group study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.